Document is current
Any future updates will be listed below
-
Authors
Johnson, Jeffrey S.
Miller, Justin W.
Hatoum, Firas
Schell, Michael J. https://orcid.org/0000-0003-4594-6601
Yu, Xiaoqing https://orcid.org/0000-0003-4585-9372
Roman Souza, Gabriel
Mizelle, Sarah
Gullapalli, Keerthi
Fazili, Adnan
Jain, Rohit
Chatzkel, Jonathan
Cen, Ling
Dhillon, Jasreman https://orcid.org/0000-0001-6785-3487
Cubitt, Christopher https://orcid.org/0000-0001-6343-7451
Yao, Jiqiang
Whiting, Junmin
Li, Jiannong
Swank, Jennifer
Jameel, Ghazal
Zhang, Jingsong https://orcid.org/0000-0003-1192-5116
Wang, Xuefeng https://orcid.org/0000-0001-5775-408X
Spiess, Philippe E. https://orcid.org/0000-0002-5723-1972
Fishman, Mayer
Chahoud, Jad https://orcid.org/0000-0002-8435-0264
- License Information
-
More Information
Article History
Received: 2 February 2026
Accepted: 11 May 2026
First Online: 25 May 2026
Competing interests
: Jo.C.: has received funding from Aveo, Genentech, Merck, and Exelixis for the conduct of clinical trials. G.J.: advisory board Astellas and Pfizer, honorarium for non-branded programs supported by DAVA Oncology. P.E.S.: Paid consultant for MyCareAlgorithm. M.F.: During the period the trial was active, M.F. received honoraria or advisory board, or speaker board payments, including Astellas, AVEO, Bayer, Bristol Myers Squib, Carsgen, Eisai, Exelixis, Immatics, Merck, Pfizer, and Prometheus. J.C.: J.C. has received advisory board or consultancy fees during his lifetime from Merck, Pfizer, Exelixis, Aveo, Eisai, and Mycaregorythm. J.C. is an editor for PDQ NCI. J.C. received honorarium for non-branded educational programs supported by DAVA Oncology and MJH Life Sciences. J.C. has received research funding during his lifetime (to J.C.’s institution) from Allogene, Astellas, Bristol Meyers, Eisai, Eli Lilly, Exelixis, Genentech, Merck, and Pfizer. J.C. is the co-founder of AI-OS LLC.
